Maraviroc Reduces the Regulatory T-Cell Frequency in Antiretroviral-Naive HIV-Infected Subjects

CCR5 Expression Levels Influence NFAT Translocation, IL-2 Production, and Subsequent Signaling Events during T Lymphocyte Activation

(2014) J. F. Camargo et al.   JOURNAL OF IMMUNOLOGY

Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer

(2014) M. C. B. Tan et al.   JOURNAL OF IMMUNOLOGY

Unknown

(2013) Samantha Westrop et al.   MOLECULAR MEDICINE

The CCL5/CCR5 axis promotes metastasis in basal breast cancer

(2013) Marco Velasco-Velázquez et al.   OncoImmunology

Effect of Maraviroc on HIV Disease Progression-Related Biomarkers

(2012) M. Concepción Romero-Sánchez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The split personality of regulatory T cells in HIV infection

(2012) M. F. Chevalier et al.   BLOOD

Tumor-Derived Chemokine CCL5 Enhances TGF- -Mediated Killing of CD8+ T Cells in Colon Cancer by T-Regulatory Cells

(2012) L.-Y. Chang et al.   CANCER RESEARCH

CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells

(2012) M. Velasco-Velazquez et al.   CANCER RESEARCH

Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients

(2012) Anthony Mills et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth

(2012) E. Schlecker et al.   JOURNAL OF IMMUNOLOGY

A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4+ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256

(2012) T. J. Wilkin et al.   JOURNAL OF INFECTIOUS DISEASES

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

(2012) Ran Reshef et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longitudinal Changes of Peripheral Blood DC Subsets and Regulatory T Cells in Chinese Chronic HIV-1-Infected Patients during Antiretroviral Therapy

(2012) Mei Zhang et al.   PLoS One

Analysis of Suppressor and Non-Suppressor FOXP3+ T Cells in HIV-1-Infected Patients

(2012) Lourdes Arruvito et al.   PLoS One

CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities

(2011) Timothy J. Wilkin et al.   Annual Review of Medicine

Targeting Regulatory T Cells in Cancer

(2011) W. L. Byrne et al.   CANCER RESEARCH

In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells

(2011) R. Rossi et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2

(2010) David M Asmuth et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

CCR5 Dictates the Equilibrium of Proinflammatory IL-17+ and Regulatory Foxp3+ T Cells in Fungal Infection

(2010) D. N. Kroetz et al.   JOURNAL OF IMMUNOLOGY

Normalization of FoxP3+ Regulatory T Cells in Response to Effective Antiretroviral Therapy

(2010) Martin Montes et al.   JOURNAL OF INFECTIOUS DISEASES

Increased Regulatory T Cell Counts in HIV‐Infected Nonresponders to Hepatitis B Virus Vaccine

(2010) María del Mar del Pozo Balado et al.   JOURNAL OF INFECTIOUS DISEASES

Relationship between Regulatory T Cells and Immune Activation in Human Immunodeficiency Virus-Infected Patients Interrupting Antiretroviral Therapy

(2010) Laurence Weiss et al.   PLoS One

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients

(2010) Nicholas Funderburg et al.   PLoS One

Correlation between the Trofile(R) test and virological response to a short-term maraviroc exposure in HIV-infected patients

(2009) M. Genebat et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1

(2009) Michael Saag et al.   JOURNAL OF INFECTIOUS DISEASES

CD4+CD25+/hiCD127loPhenotype Does Not Accurately Identify Regulatory T Cells in All Populations of HIV‐Infected Persons

(2009) Maria del Mar del Pozo‐Balado et al.   JOURNAL OF INFECTIOUS DISEASES

Human Regulatory T Cells Are Targets for Human Immunodeficiency Virus (HIV) Infection, and Their Susceptibility Differs Depending on the HIV Type 1 Strain

(2009) M. E. Moreno-Fernandez et al.   JOURNAL OF VIROLOGY

Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy

(2008) J. C. Gaardbo et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs

(2008) L. Kolte et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection

(2008) Sharon S. Lieberman-Blum et al.   CLINICAL THERAPEUTICS

High frequency and proliferation of CD4+FOXP3+ Treg in HIV-1-infected patients with low CD4 counts

(2008) Xiuqiong Bi et al.   EUROPEAN JOURNAL OF IMMUNOLOGY